Jakub Bukowczan1, Zygmunt Warzecha2, Piotr Ceranowicz2, Beata Kuśnierz-Cabala3, Romana Tomaszewska4, Artur Dembinski2. 1. Department of Endocrinology and Diabetes Mellitus, Northumbria NHS Foundation Trust, Rake Lane, NE28 8NH North Shields, Tyne and Wear, United Kingdom. Electronic address: jakubbukowczan@gmail.com. 2. Department of Physiology, Jagiellonian University Medical College, Krakow, Poland. 3. Department of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland. 4. Department of Pathology, Jagiellonian University Medical College, Krakow, Poland.
Abstract
UNLABELLED: Obestatin, as ghrelin, has been originally extracted from the stomach, which remains its major source. Previous studies have shown that administration of obestatin exhibits protective and healing-promoting effects in several organs, including the stomach and kidney. In pancreas, pretreatment with obestatin inhibits the development of cerulein-induced acute pancreatitis and promotes survival of pancreatic beta cells and human islets. The aim of the present study was to check the universality of protective effect of obestatin in the pancreas. For this reason we investigated the influence of obestatin administration on the development of ischemia/reperfusion-induced pancreatitis. Acute pancreatitis was induced by pancreatic ischemia followed by reperfusion of the gland. Obestatin (4, 8 or 16 nmol/kg/dose) was administered intraperitoneally twice: 0.5h before exposure to ischemia, and 3h after the first injection. The effect of obestatin on the course of necrotizing pancreatitis was assessed after 6-h reperfusion, and included histological, functional, and biochemical analyses. Treatment with obestatin reduced morphological signs of pancreatic damage including edema, vacuolization of acinar cells, hemorrhages, acinar necrosis, and leukocyte infiltration of the gland. These effects were accompanied by an improvement of pancreatic DNA synthesis and superoxide dismutase activity, and a decrease in serum level of lipase and pro-inflammatory interleukin-1β. Moreover pretreatment with obestatin reduced myeloperoxidase activity and malondialdehyde concentration in pancreatic tissue of rats with acute pancreatitis. CONCLUSIONS: Administration of obestatin inhibits the development of ischemia/reperfusion-induced acute pancreatitis. This observation, taken together with previous findings that obestatin protects the pancreas against cerulein-induced pancreatitis, indicates that protective effect of obestatin in the pancreas is universal and independent of the primary cause of acute pancreatitis.
UNLABELLED: Obestatin, as ghrelin, has been originally extracted from the stomach, which remains its major source. Previous studies have shown that administration of obestatin exhibits protective and healing-promoting effects in several organs, including the stomach and kidney. In pancreas, pretreatment with obestatin inhibits the development of cerulein-induced acute pancreatitis and promotes survival of pancreatic beta cells and human islets. The aim of the present study was to check the universality of protective effect of obestatin in the pancreas. For this reason we investigated the influence of obestatin administration on the development of ischemia/reperfusion-induced pancreatitis. Acute pancreatitis was induced by pancreatic ischemia followed by reperfusion of the gland. Obestatin (4, 8 or 16 nmol/kg/dose) was administered intraperitoneally twice: 0.5h before exposure to ischemia, and 3h after the first injection. The effect of obestatin on the course of necrotizing pancreatitis was assessed after 6-h reperfusion, and included histological, functional, and biochemical analyses. Treatment with obestatin reduced morphological signs of pancreatic damage including edema, vacuolization of acinar cells, hemorrhages, acinar necrosis, and leukocyte infiltration of the gland. These effects were accompanied by an improvement of pancreatic DNA synthesis and superoxide dismutase activity, and a decrease in serum level of lipase and pro-inflammatory interleukin-1β. Moreover pretreatment with obestatin reduced myeloperoxidase activity and malondialdehyde concentration in pancreatic tissue of rats with acute pancreatitis. CONCLUSIONS: Administration of obestatin inhibits the development of ischemia/reperfusion-induced acute pancreatitis. This observation, taken together with previous findings that obestatin protects the pancreas against cerulein-induced pancreatitis, indicates that protective effect of obestatin in the pancreas is universal and independent of the primary cause of acute pancreatitis.
Authors: Omer Uslukaya; Ahmet Turkoglu; Umit Can Yazgan; Ibrahim Kaplan; Ibrahim Ibiloglu; Murat Kapan; Metehan Gumus Journal: Surg Today Date: 2016-03-16 Impact factor: 2.549
Authors: Jakub Bukowczan; Zygmunt Warzecha; Piotr Ceranowicz; Beata Kuśnierz-Cabala; Romana Tomaszewska Journal: PLoS One Date: 2015-07-30 Impact factor: 3.240
Authors: Aleksandra Matuszyk; Piotr Ceranowicz; Zygmunt Warzecha; Jakub Cieszkowski; Joanna Bonior; Jolanta Jaworek; Beata Kuśnierz-Cabala; Peter Konturek; Tadeusz Ambroży; Artur Dembiński Journal: Oxid Med Cell Longev Date: 2015-12-20 Impact factor: 6.543
Authors: Zygmunt Warzecha; Paweł Sendur; Piotr Ceranowicz; Marcin Dembiński; Jakub Cieszkowski; Beata Kuśnierz-Cabala; Rafał Olszanecki; Romana Tomaszewska; Tadeusz Ambroży; Artur Dembiński Journal: Int J Mol Sci Date: 2016-10-12 Impact factor: 5.923
Authors: Aleksandra Matuszyk; Piotr Ceranowicz; Zygmunt Warzecha; Jakub Cieszkowski; Krystyna Gałązka; Joanna Bonior; Jolanta Jaworek; Peter Christopher Konturek; Krzysztof Gil; Artur Dembiński Journal: Arch Med Sci Date: 2016-03-23 Impact factor: 3.318
Authors: Katarzyna Konarska; Jakub Cieszkowski; Zygmunt Warzecha; Piotr Ceranowicz; Anna Chmura; Beata Kuśnierz-Cabala; Krystyna Gałązka; Paweł Kowalczyk; Andrzej Miskiewicz; Thomas Jan Konturek; Michał Pędziwiatr; Artur Dembiński Journal: Int J Mol Sci Date: 2018-06-01 Impact factor: 5.923